

Leronlimab (PRO 140)

HIV (combination-Mono-PrEP-Cure)

Cancer (mTNBC-mCRC)

GvHD – NASH


Licensing & Partnering Opportunities

Annual Shareholder Meeting
September 12, 2019

Presenters

Dr. Nader Pourhassan, President & CEO

Mr. Michael Mulholland, CFO



HIV Combo.	HIV Mono.	HIV-PrEP	Non-HIV	Manufac.
Dec 5, 2014 Phase 3-p	Feb 18, 2014 HIV-Phase 2	Jun 17, 2019– MOU	Dec 14, 2015 GvHD	Apr 02, 2019 Samsung
Oct 6, 2016 0.7log-0.5log	Dec 5, 2014 Phase 2-Ext		Nov26,2018 mTNBC	
Feb 20,2018 PrimaryEndP	Feb 23, 2016 Phase 3		Sep 04, 2019 NASH	
Jun 22, 2018 FDA - BLA	100 Patients Safety /BLA		Sep 09, 2019 mCRC	
Mar 4, 2019 RollingR. BLA	~600 Patient. Safety-BLA			
Aug 28, 2019 FDA-BLA	Aug 28, 2019 FDA-Pivotal			
Licensing HIV Indication			Launching a Product \$50 million	
			Partnering Potentials	

Potential Licensing and/or Partnering

Potential licensing out sales of leronlimab in US alone

Potential licensing out sales of leronlimab in EU and other 8MM

Partnering/licensing of all non-HIV indications

Up-listing CytoDyn to NYSE or NASDAQ and/or Hong Kong exchange

HIV Combination - BLA Timeline

HIV

- 1) Combination Therapy
- 2) Monotherapy
- 3) PrEP
- 4) Cure

mTNBC – First Patient injection timeline?

- 1) IND/Protocol filed – FDA green light to proceed
- 2) First patients injection

mCRC

IND/Protocol filed – FDA green light to proceed

NASH

IND/Protocol filed

GvHD

First patient injection

Diagnostic

- 1) Prognostic test
- 2) Leronlimab used as a diagnostic tool for CCR5 recognition

CytoDyn Price/Volume Trade/Fund Raised

	Stock avg (\$)	Total Volume	Volume/day	Self-Placed (\$)	Total (\$)
2008	0.44	1,319,100	5,214	1,268,000	1,268,000
2009	0.77	1,443,800	5,729	2,222,200	2,222,200
2010	1.50	2,494,400	9,898	2,181,000	2,181,000
2011	2.26	5,734,100	22,754	4,431,861	4,431,861
2012	1.66	9,448,600	37,794	6,156,750	6,156,750
2013	0.93	6,446,800	25,583	1,358,500	15,858,500
2014	0.86	15,181,700	60,245	2,777,333	2,777,333
2015	0.87	20,628,700	81,860	5,676,603	24,693,613
2016	0.93	68,135,900	270,381	9,432,498	33,397,503
2017	0.65	48,672,800	193,146	6,218,500	22,504,057
2018	0.56	70,710,900	280,599	10,932,900	48,939,013
2019	0.47	81,654,800	469,387	26,027,232	42,472,772
		118 million		78,683,377	206,902,602